会议报告：癌症预防药物研发中的转化进展会议
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.
作者信息
Miller Mark Steven, Allen Peter J, Brown Powel H, Chan Andrew T, Clapper Margie L, Dashwood Roderick H, Demehri Shadmehr, Disis Mary L, DuBois Raymond N, Glynn Robert J, Kensler Thomas W, Khan Seema A, Johnson Bryon D, Liby Karen T, Lipkin Steven M, Mallery Susan R, Meuillet Emmanuelle J, Roden Richard B S, Schoen Robert E, Sharp Zelton D, Shirwan Haval, Siegfried Jill M, Rao Chinthalapally V, You Ming, Vilar Eduardo, Szabo Eva, Mohammed Altaf
机构信息
Chemopreventive Agent Development Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, Maryland, USA.
Division of Surgical Oncology, Duke Cancer Institute, Durham, NC, USA.
出版信息
J Cancer Prev. 2021 Mar 30;26(1):71-82. doi: 10.15430/JCP.2021.26.1.71.
The Division of Cancer Prevention of the National Cancer Institute (NCI) and the Office of Disease Prevention of the National Institutes of Health co-sponsored the Translational Advances in Cancer Prevention Agent Development Meeting on August 27 to 28, 2020. The goals of this meeting were to foster the exchange of ideas and stimulate new collaborative interactions among leading cancer prevention researchers from basic and clinical research; highlight new and emerging trends in immunoprevention and chemoprevention as well as new information from clinical trials; and provide information to the extramural research community on the significant resources available from the NCI to promote prevention agent development and rapid translation to clinical trials. The meeting included two plenary talks and five sessions covering the range from pre-clinical studies with chemo/immunopreventive agents to ongoing cancer prevention clinical trials. In addition, two NCI informational sessions describing contract resources for the preclinical agent development and cooperative grants for the Cancer Prevention Clinical Trials Network were also presented.
美国国立癌症研究所（NCI）癌症预防司与美国国立卫生研究院疾病预防办公室于2020年8月27日至28日联合主办了癌症预防药物开发转化进展会议。本次会议的目标是促进思想交流，激发基础研究和临床研究领域顶尖癌症预防研究人员之间新的合作互动；突出免疫预防和化学预防的新趋势以及临床试验的新信息；并向外部研究界提供有关NCI可用于促进预防药物开发和快速转化为临床试验的重要资源的信息。会议包括两场全体会议和五场会议，内容涵盖从化学/免疫预防药物的临床前研究到正在进行的癌症预防临床试验。此外，还举办了两场NCI信息会议，介绍临床前药物开发的合同资源以及癌症预防临床试验网络的合作资助情况。
Zotero 插件